Rivaroxaban With or Without Aspirin in Patients With S
An International, Randomised, Double-Blind, Placebo-C

Lancet, The

391, 205-218

DOI: 10.1016/s0140-6736(17)32458-3

Citation Report

#	Article	IF	Citations
1	COMPASS-Guided Secondary Prevention. Nature Reviews Cardiology, 2017, .	62.4	0
2	Exercise Rehabilitation for Peripheral Artery Disease: A Review. Journal of Cardiopulmonary Rehabilitation and Prevention, 2018, 38, 63.	2.2	87
3	Weighing the Anti-Ischemic Benefits and Bleeding Risks From Aspirin Therapy: A Rational Approach. Current Atherosclerosis Reports, 2018, 20, 1-14.	7.3	7
4	Oral Anticoagulant Use in Cardiovascular Disorders: A Perspective on Present and Potential Indications for Rivaroxaban. Current Medical Research and Opinion, 2018, 34, 1945-1957.	2.9	5
5	Return of Oral Anticoagulation in Chronic Stable Coronary Disease. Circulation, 2018, 137, 1655-1657.	24.6	3
6	Introduction to the Vascular Medicine Issue of Progress in Cardiovascular Diseases. Progress in Cardiovascular Diseases, 2018, 60, 565-566.	9.7	2
7	Rivaroxaban Plus Aspirin, Compared With Aspirin Alone, Reduced Cardiovascular Events in Patients With Stable Peripheral or Carotid Artery Disease, but Increased the Risk of Major Bleeding. BMJ Evidence-Based Medicine, 2018, 23, 191-192.	8.4	2
8	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-Analysis. JAMA Cardiology, 2018, 3, 234-241.	16.3	57
9	Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 726-732.	7.9	24
10	Rivaroxaban in Stable Cardiovascular Disease. New England Journal of Medicine, 2018, 378, 397-398.	76.6	6
11	Anticoagulant and Antiplatelet Therapy Choices for Patients With Atrial Fibrillation One Year After Coronary Stenting or Acute Coronary Syndrome. Expert Opinion on Drug Safety, 2018, 17, 251-258.	3.2	3
12	Advances in Atherosclerosis, Atrial Fibrillation, and Valvular Disease. Nature Reviews Cardiology, 2018, 15, 71-72.	62.4	6
13	Peripheral Vascular Disease Risk in Diabetic Individuals Without Coronary Heart Disease. Atherosclerosis, 2018, 275, 419-425.	7.0	35
14	The Coagulation System in Atherothrombosis: Implications for New Therapeutic Strategies. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 188-198.	3.3	80
15	Predictors of Bleeding in Patients With Symptomatic Peripheral Artery Disease: A Cohort Study Using the Health Improvement Network in the United Kingdom. Thrombosis and Haemostasis, 2018, 118, 1101-1112.	4.6	12
16	Nuevos enfoques farmacológicos para el riesgo cardiovascular. Medicina Clínica, 2018, 151, 145-147.	1.2	1
17	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. Journal of the American College of Cardiology, 2018, 71, 2306-2315.	12.0	441
18	Recurrent Thrombosis in Patients With Antiphospholipid Antibodies Treated With Vitamin K Antagonists or Rivaroxaban. Haematologica, 2018, 103, e315-e317.	3.9	43

#	Article	IF	Citations
19	12 Months of DAPT After Acute Coronary Syndrome Still Beats 6 Months. Lancet, The, 2018, 391, 1240-1242.	96.9	8
20	Rivaroxaban Plus Aspirin in CAD or PAD. Nature Reviews Cardiology, 2018, 15, 3-3.	62.4	1
21	Antithrombotic Therapy in Peripheral Artery Disease. Lancet, The, 2018, 391, 183-184.	96.9	8
22	Secondary Prevention Shifts Into Second Gear. Lancet, The, 2018, 391, 181-182.	96.9	2
23	Antiplatelet Therapy for Peripheral Artery Disease. Cardiovascular Diagnosis and Therapy, 2018, 8, 66377-66677.	2.1	10
24	Acute Limb Ischemia Therapies: When and How to Treat Endovascularly. Seminars in Interventional Radiology, 2018, 35, 453-460.	1.1	25
25	Low-Dose Rivaroxaban Plus Aspirin for the Prevention of Cardiovascular Events: An Evaluation of COMPASS. Future Cardiology, 2018, 14, 443-453.	1.2	8
26	Asymptomatic Carotid Stenosis: Intervention or Best Medical Therapy?. Current Neurology and Neuroscience Reports, 2018, 18, 1-9.	8.7	45
27	Lower Extremity Arterial Disease in Patients With Diabetes: A Contemporary Narrative Review. Cardiovascular Diabetology, 2018, 17, 1-14.	15.7	150
28	Pathology of Arterial Disease in Limb Loss: The Clot Thickens. Journal of the American College of Cardiology, 2018, 72, 2164-2165.	12.0	1
29	Antithrombotic Therapy in Abdominal Aortic Aneurysm: Beneficial or Detrimental?. Blood, 2018, 132, 2619-2628.	10.6	80
30	Randomized Trial of Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Atherosclerosis. American Heart Journal, 2018, 206, 127-130.	3.3	49
31	Antiplatelet Treatment for Catheter-Based Interventions in High-Risk Patients: Current Guidelines and Expert Opinion. Hamostaseologie, 2018, 38, 229-235.	1.5	2
32	Anticoagulation in Atherosclerotic Disease. Hamostaseologie, 2018, 38, 240-246.	1.5	17
33	Novel Aspects of Antiplatelet Therapy in Cardiovascular Disease. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 439-449.	3.3	49
34	Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease. Critical Pathways in Cardiology, 2018, 17, 53.	1.0	1
35	Ischemia and Bleeding on the Horns of a Dilemma: Do Only Hard Endpoints Count?. Journal of the American College of Cardiology, 2018, 72, 137-140.	12.0	1
36	Advances in Clinical Cardiology 2017: A Summary of Key Clinical Trials. Advances in Therapy, 2018, 35, 899-927.	5.0	2

#	Article	IF	Citations
37	Antithrombotische Therapie Bei Peripherer Arterieller Verschlusskrankheit. Deutsche Medizinische Wochenschrift, 2018, 143, 1060-1064.	0.3	8
38	Recent Advances in Primary and Secondary Prevention of Atherosclerotic Stroke. Journal of Stroke, 2018, 20, 145-166.	7.6	56
39	A Practical Review of the Emerging Direct Anticoagulants, Laboratory Monitoring, and Reversal Agents. Journal of Clinical Medicine, 2018, 7, 29.	3.8	34
40	Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. Journal of Clinical Medicine, 2018, 7, 74.	3.8	6
41	Preventing Major Amputations in Patients With Critical Limb Ischemia. Current Cardiology Reports, 2018, 20, 1-7.	4.5	19
42	Perspektiven der Atherothrombosetherapie nach der COMPASS-Studie. Klinikarzt, 2018, 47, 172-175.	0.0	0
43	Was bringt die duale Sekundärprävention bei PAVK und bei KHK?. CardioVasc, 2018, 18, 49-49.	0.0	0
44	Association of Intracranial Hemorrhage Risk With Non–Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-Analysis. JAMA Neurology, 2018, 75, 1511-1518.	22.0	25
45	Aspirin—Still the GLOBAL LEADER in Antiplatelet Therapy. Lancet, The, 2018, 392, 896-897.	96.9	7
46	Dual Pathway Inhibition With Low-Dose Direct Factor Xa Inhibition After Acute Coronary Syndromes—Why Is It Not Used in Clinical Practice?. Thrombosis and Haemostasis, 2018, 118, 1528-1534.	4.6	4
47	Individualized Antithrombotic Therapy in High-Risk Cardiovascular Patients. Personalized Medicine, 2018, 15, 223-236.	1.1	1
48	Role of Oral Anticoagulant Therapy for Secondary Prevention in Patients With Stable Atherothrombotic Disease Manifestations. Therapeutic Advances in Hematology, 2019, 10, 2040620719861475.	2.8	5
49	Endovascular Management of Saccular Extracranial Internal Carotid Artery Aneurysm Using Transcervical Carotid Approach and Flow Reversal. Journal of Vascular Surgery Cases and Innovative Techniques, 2019, 5, 273-277.	0.9	12
50	Usefulness of Coronary Artery Calcium to Identify Adults of Sufficiently High Risk for Atherothrombotic Cardiovascular Events to Consider Low-Dose Rivaroxaban Thromboprophylaxis (From MESA). American Journal of Cardiology, 2019, 124, 1198-1206.	2.4	12
51	Pharmacological Therapy of Peripheral Artery Disease in Patients With Diabetes Mellitus: Cardiovascular Risk Factor Management. Journal of Korean Diabetes, 2019, 20, 24-32.	0.5	1
52	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. Journal of the American College of Cardiology, 2019, 73, 3271-3280.	12.0	124
53	Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). Journal of the American College of Cardiology, 2019, 74, 699-711.	12.0	33
54	Heterogeneity of Risk and Benefit in Subgroups of COMPASS: Relatively Similar but Absolutely Different. Journal of the American College of Cardiology, 2019, 73, 3292-3294.	12.0	1

#	Article	IF	Citations
55	Role of Rivaroxaban in the Prevention of Atherosclerotic Events. Expert Review of Clinical Pharmacology, 2019, 12, 771-780.	3.6	16
56	Qing-Xin-Jie-Yu Granule for Patients With Stable Coronary Artery Disease (QUEST Trial): A Multicenter, Double-Blinded, Randomized Trial. Complementary Therapies in Medicine, 2019, 47, 102209.	4.3	20
57	Rivaroxaban Plus Aspirin for Cardiovascular Protection: Rationale for the Vascular Dose and Dual Pathway Inhibition. Thrombosis Research, 2019, 184, 44-49.	2.9	9
58	Dual Antiplatelet Therapy After Endovascular Revascularization of Infrainguinal Arteries. Vascular Medicine, 2019, 24, 536-538.	2.3	3
59	Implications for REDUCE IT in Clinical Practice. Progress in Cardiovascular Diseases, 2019, 62, 395-400.	9.7	12
60	Ischemic and Bleeding Outcomes of Triple Therapy in Patients on Chronic Anticoagulation Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials. JRSM Cardiovascular Disease, 2019, 8, 2048004019885572.	0.9	3
61	One Simple Claudication Question as First Step in Peripheral Arterial Disease (PAD) Screening: A Meta-Analysis of the Association With Reduced Ankle Brachial Index (ABI) in 27,945 Subjects. PLoS ONE, 2019, 14, e0224608.	3.2	14
62	Perspektive nach der COMPASS-Studie für KHK- und AVK-Patienten. Klinikarzt, 2019, 48, 73-77.	0.0	1
63	Ticagrelor in Patients With Diabetes and Stable Coronary Artery Disease With a History of Previous Percutaneous Coronary Intervention (THEMIS-PCI): A Phase 3, Placebo-Controlled, Randomised Trial. Lancet, The, 2019, 394, 1169-1180.	96.9	198
64	Rivaroxaban and Aspirin in Peripheral Vascular Disease: A Review of Implementation Strategies and Management of Common Clinical Scenarios. Current Cardiology Reports, 2019, 21, 1-9.	4.5	21
65	Estimating Individual Lifetime Benefit and Bleeding Risk of Adding Rivaroxaban to Aspirin for Patients With Stable Cardiovascular Disease: Results From the COMPASS Trial. European Heart Journal, 2019, 40, 3771-3778a.	14.7	35
66	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. Circulation, 2019, 140, 1451-1459.	24.6	44
67	Is Bleeding Always Bad?: Bad Boy Bleeding. Journal of the American College of Cardiology, 2019, 74, 1529-1531.	12.0	1
68	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology, 2019, 74, 1519-1528.	12.0	42
69	The Continuous Challenge of Antithrombotic Strategies in Diabetes: Focus on Direct Oral Anticoagulants. Acta Diabetologica, 2019, 56, 1247-1258.	3.8	7
70	Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. Drug Safety, 2019, 42, 1409-1422.	5.9	13
71	Arzneiverordnungs-Report 2019. , 2019, .		89
72	Akutes Koronarsyndrom. Herz, 2019, 44, 45-52.	1.8	1

#	Article	IF	Citations
73	Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease. Circulation Research, 2019, 124, 416-425.	15.7	41
74	Management of Patients With Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. Thrombosis and Haemostasis, 2019, 119, 576-585.	4.6	12
75	Interventionelle Angiologie. Der Internist, 2019, 60, 149-160.	0.7	0
76	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2019, 69, 3S-125S.e40.	3.4	1,544
77	The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARMα) Paradigm: Conceptual Framework and Therapeutic Potential. Cardiovascular Diabetology, 2019, 18, 1-20.	15.7	132
78	Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. European Journal of Vascular and Endovascular Surgery, 2019, 58, S1-S109.e33.	3.2	1,478
79	Ticagrelor Improves Blood Viscosity-Dependent Microcirculatory Flow in Patients With Lower Extremity Arterial Disease: The Hema-Kinesis Clinical Trial. Cardiovascular Diabetology, 2019, 18, 1-9.	15.7	13
80	Antiagrégant et Anticoagulant En Association Dans La Maladie Coronaire Chronique : Rationnel D'Une Double Voie D'Inhibition: Combination of Antiplatelet and Oral Anticoagulation for Chronic Coronary Artery Disease: What Is the Rationale?. Archives of Cardiovascular Diseases Supplements, 2019, 11, S11-S19.	0.0	0
81	Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ?: Management of chronic coronary artery disease: are new guidelines warranted?. Archives of Cardiovascular Diseases Supplements, 2019, 11, S28-S39.	0.0	0
82	Un risque thrombotique persistant malgré les traitements de référence: A residual thrombotic risk despite recommended treatments. Archives of Cardiovascular Diseases Supplements, 2019, 11, S4-S10.	0.0	0
83	Advances in the Management of Peripheral Artery Disease. Current Diabetes Reports, 2019, 19, 1-7.	9.0	7
84	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circulation Research, 2019, 124, 1520-1535.	15.7	163
85	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. Journal of the American College of Cardiology, 2019, 73, 2243-2250.	12.0	49
86	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit – ein Überblick über aktuelle Evidenz, Praxis und Ausblick. Deutsche Medizinische Wochenschrift, 2019, 144, 683-689.	0.3	1
87	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. Circulation, 2019, 139, 2170-2185.	24.6	93
88	From Heart to Head, Thrombi to Emboli, and Inferences to Extrapolation. Journal of the American College of Cardiology, 2019, 73, 1000-1003.	12.0	5
89	Incidence and Cost of Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease. American Journal of Cardiology, 2019, 123, 1893-1899.	2.4	53
90	Predicting Future Cardiovascular Events in Patients With Peripheral Artery Disease Using Electronic Health Record Data. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004741.	5.6	72

#	Article	IF	Citations
91	Rivaroxaban Suppresses the Progression of Ischemic Cardiomyopathy in a Murine Model of Diet-Induced Myocardial Infarction. Journal of Atherosclerosis and Thrombosis, 2019, 26, 915-930.	3.7	31
92	Inadequate Control of Atherosclerotic Cardiovascular Disease Risk Factors in Europe: EUROASPIRE Repeats Itself. European Journal of Preventive Cardiology, 2019, 26, 820-823.	6.1	11
93	The Year in Cardiology 2018: Heart Failure. European Heart Journal, 2019, 40, 651-661.	14.7	34
94	Antithrombotic Therapy After Femoropopliteal Artery Stenting: 12-Month Results From Japan Postmarketing Surveillance. Heart Asia, 2019, 11, e011114.	1.8	4
95	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA) sowie der Deutschen Gesellschaft für Interventionelle Radiologie (DeGIR). Diabetologie Und Stoffwechsel, 2019, 14, S258-S266.	0.2	1
96	Antikoagulation Bei Chronischer Koronarer Herzkrankheit. Klinikarzt, 2019, 48, 82-85.	0.0	0
97	Effect of Coexisting Vascular Disease on Long-Term Risk of Recurrent Events After TIA or Stroke. Neurology, 2019, 93, e695-e707.	5.0	25
98	Potential of Multidimensional, Large-Scale Biodatabases to Elucidate Coagulation and Platelet Pathways as an Approach Towards Precision Medicine in Thrombotic Disease. Hamostaseologie, 2019, 39, 152-163.	1.5	9
99	Applying Contemporary Antithrombotic Therapy in the Secondary Prevention of Chronic Atherosclerotic Cardiovascular Disease. American Heart Journal, 2019, 218, 100-109.	3.3	7
100	Konservative Therapie der pAVK. Klinikarzt, 2019, 48, 181-185.	0.0	1
101	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People With Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S105-S113.	1.9	15
102	Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) Post-Percutaneous Coronary Intervention: A Network Meta-Analysis. Cochrane Database of Systematic Reviews, 2019, 12, CD013252.	6.9	11
103	Dual-Pathway-Inhibition Bei Atherosklerose – Wer Profitiert?. Deutsche Medizinische Wochenschrift, 2019, 144, 1384-1389.	0.3	2
104	Antithrombotic Therapy and Revascularisation Strategies in People With Diabetes and Coronary Artery Disease. European Journal of Preventive Cardiology, 2019, 26, 92-105.	6.1	9
105	COMPASS for Vascular Surgeons: Practical Considerations. Current Opinion in Cardiology, 2019, 34, 178.	2.2	8
106	Coagulation Signalling and Metabolic Disorders: Lessons Learned From Animal Models. Hamostaseologie, 2019, 39, 164-172.	1.5	6
107	There May Be a Role for Addition of Rivaroxaban to Aspirin in Patients With Stable Coronary Artery Disease. BMJ Evidence-Based Medicine, 2019, 24, 78-79.	8.4	0
108	Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. American Journal of Cardiovascular Drugs, 2019, 19, 37-47.	3.7	7

#	Article	IF	Citations
109	TLR4-Dependent Upregulation of the Platelet NLRP3 Inflammasome Promotes Platelet Aggregation in a Murine Model of Hindlimb Ischemia. Biochemical and Biophysical Research Communications, 2019, 508, 614-619.	2.6	34
110	The FAST-MI 2005-2010-2015 Registries in the Light of the COMPASS Trial: The COMPASS Criteria Applied to a Post-MI Population. International Journal of Cardiology, 2019, 278, 7-13.	3.2	23
111	Exosomes Derived miR-126 Attenuates Oxidative Stress and Apoptosis From Ischemia and Reperfusion Injury by Targeting ERRFI1. Gene, 2019, 690, 75-80.	2.9	55
112	The Year in Cardiology 2018: Prevention. European Heart Journal, 2019, 40, 336-344.	14.7	38
113	Periphere Arterielle Verschlusskrankheit Als Prädiktor Einer Hohen Atheroskleroselast. Herz, 2019, 44, 40-44.	1.8	4
114	Prevention of Atherothrombotic Events in Patients With Diabetes Mellitus: From Antithrombotic Therapies to New-Generation Glucose-Lowering Drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	62.4	102
115	The Myth of 'Stable' Coronary Artery Disease. Nature Reviews Cardiology, 2020, 17, 9-21.	62.4	137
116	2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. European Heart Journal, 2020, 41, 407-477.	14.7	6,554
117	2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration With the EASD. European Heart Journal, 2020, 41, 255-323.	14.7	3,732
118	Applying Evidence-Based Antiplatelet Therapy in Patients Following a Myocardial Infarction Without Percutaneous Coronary Revascularization. European Heart Journal, 2020, 41, 1633-1635.	14.7	1
119	Low-Dose Aspirin Treatment Attenuates Male Rat Salt-Sensitive Hypertension via Platelet Cyclooxygenase 1 and Complement Cascade Pathway. Journal of the American Heart Association, 2020, 9, e013470.	5.8	30
120	Arzneiverordnungs-Report 2020. , 2020, .		89
121	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiology, 2021, 6, 21-29.	16.3	89
122	Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review. Journal of the American Heart Association, 2020, 9, e015361.	5.8	18
123	An Updated Drug Profile of Ticagrelor With Considerations on the Treatment of Patients With Coronary Artery Disease and Diabetes Mellitus. Expert Review of Cardiovascular Therapy, 2020, 18, 449-464.	2.7	11
124	Chronic Ischaemic Heart Disease and Rivaroxaban: Which Patients Derive the Greatest Benefit?. European Heart Journal Supplements, 2020, 22, L24-L27.	2.9	5
125	Atrial Fibrillation and Ischaemic Heart Disease: Should We Use Acetylsalicylic Acid Beside Anticoagulants?. European Heart Journal Supplements, 2020, 22, L166-L169.	2.9	8
126	Antithrombotische Therapie des chronischen Koronarsyndroms. Klinikarzt, 2020, 49, 97-101.	0.0	0

#	Article	IF	Citations
127	Aspirin and Low-Dose Rivaroxaban – The Dual Pathway Concept in Patients With Stable Atherosclerotic Disease: A Comprehensive Review. Expert Review of Cardiovascular Therapy, 2020, 18, 577-585.	2.7	3
128	The COMPASS Trial: Practical Considerations for Application After Coronary Artery Bypass Surgery. Current Opinion in Cardiology, 2020, 35, 583.	2.2	1
129	Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease. Future Cardiology, 2020, 16, 597-611.	1.2	2
130	Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis. Handbook of Experimental Pharmacology, 2020, 270, 103-130.	0.0	17
131	Xarelto Plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis (XATOA): Rationale and Design of a Prospective Registry Study to Assess Rivaroxaban 2.5 mg Twice Daily Plus Aspirin for Prevention of Atherothrombotic Events in Coronary Artery Disease, Peripheral Artery Disease, or Both. American Heart Journal, 2020, 222, 166-173.	3.3	24
132	Genetic Risk Factors for Venous Thromboembolism. Expert Review of Hematology, 2020, 13, 971-981.	2.7	108
133	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents. Circulation, 2020, 142, 1425-1436.	24.6	175
134	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 2020, 76, 2252-2266.	12.0	102
135	Cardiovascular Comorbidity: Patient With Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events?. Rational Pharmacotherapy in Cardiology, 2020, 16, 607-613.	0.6	5
136	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
137	Endovascular Repair of Persistent Sciatic Artery With Limb Ischemia: A Wrong Choice?. Frontiers in Surgery, 2020, 7, 582753.	2.2	10
138	Guía ESC 2019 Sobre Diabetes, Prediabetes y Enfermedad Cardiovascular, En Colaboración Con La European Association for the Study of Diabetes (EASD). Revista Espanola De Cardiologia, 2020, 73, 404.e1-404.e59.	0.4	6
139	Clinical Significance of Thrombin Blockade With Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients. Rational Pharmacotherapy in Cardiology, 2020, 16, 99-107.	0.6	0
140	A Single-Arm Feasibility Cohort Study of Rivaroxaban in Antiphospholipid Syndrome. Pilot and Feasibility Studies, 2020, 6, 1-7.	2.5	11
141	Fibrilación auricular y cardiopatía isquémica: más allá de la prevención del ictus. Revista Espanola De Cardiologia Suplementos, 2020, 20, 11-20.	0.2	0
142	The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Frontiers in Cardiovascular Medicine, 2020, 7, 527483.	3.2	177
143	Direct Oral Anticoagulants Versus Vitamin K Antagonists in Antiphospholipid Syndrome: A Meta-Analysis. European Journal of Internal Medicine, 2020, 79, 43-50.	4.2	25
144	Statins and Major Adverse Limb Events in Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 866-875.	4.6	93

#	Article	IF	Citations
145	Effectiveness, Safety, and Major Adverse Limb Events in Atrial Fibrillation Patients With Concomitant Diabetes Mellitus Treated With Non-Vitamin K Antagonist Oral Anticoagulants. Cardiovascular Diabetology, 2020, 19, 1-14.	15.7	34
146	Treatment of Stable Ischaemic Heart Disease: The Old and the New. European Heart Journal Supplements, 2020, 22, E54-E59.	2.9	22
147	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients With Heart Failure: A Review of the Evidence. Cardiovascular Drugs and Therapy, 2020, 34, 723-735.	4.1	17
148	Kawasaki-Like Diseases and Thrombotic Coagulopathy in COVID-19: Delayed Over-Activation of the STING Pathway?. Emerging Microbes and Infections, 2020, 9, 1514-1522.	7.0	66
149	Blockade of PAR-1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin-Overexpressing Hypertensive Mice. Journal of the American Heart Association, 2020, 9, e015616.	5.8	18
150	Rivaroxaban in Patients With Ischaemic Chronic Cardiomyopathy and Obstructive Peripheral Arterial Disease: Rationale for Treatment and Results. European Heart Journal Supplements, 2020, 22, E137-E141.	2.9	1
151	Evaluation of the Safety and Efficacy of the Cobra PzF NanoCoated Coronary Stent in Routine, Consecutive, Prospective, and High-Risk Patients: The e-Cobra Study. Catheterization and Cardiovascular Interventions, 2021, 98, 45-54.	2.2	16
152	Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland. Advances in Therapy, 2020, 37, 3348-3369.	5.0	9
153	COMPASS Criteria Applied to a Contemporary Cohort of Unselected Patients With Stable Coronary Artery Diseases: Insights From the START Registry. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 513-520.	4.9	9
154	Optimal Antiplatelet and Anticoagulation Strategies in Acute Coronary Syndromes. Herz, 2020, 45, 528-536.	1.8	2
155	Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease. Circulation, 2020, 141, 1855-1858.	24.6	2
156	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). Circulation, 2020, 141, 1141-1151.	24.6	54
157	The Year 2019 in Atherosclerosis. Atherosclerosis, 2020, 299, 67-75.	7.0	0
158	Grundlagen der Angiologie bei peripherer arterieller Verschlusskrankheit (pAVK). Herz, 2020, 45, 201-208.	1.8	3
159	Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 1095-1106.	12.0	34
160	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. Circulation, 2020, 141, 1841-1854.	24.6	152
161	Prevención secundaria antitrombótica intensiva tardía luego de un infarto del miocardio ¿Cuándo, en quiénes y cómo?. Revista Colombiana De Cardiologia, 2020, 27, 1-3.	0.0	0
162	Sulodexide Improves Pain-Free Walking Distance in Patients With Lower Extremity Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. JRSM Cardiovascular Disease, 2020, 9, 2048004020907002.	0.9	6

#	Article	IF	Citations
163	Therapeutic Strategies for Thrombosis: New Targets and Approaches. Nature Reviews Drug Discovery, 2020, 19, 333-352.	91.0	387
164	Manual of Vascular Medicine. , 2020, .		0
165	Late Intensive Antithrombotic Secondary Prevention After Myocardial Infarction. When, in Whom and How?. Revista Colombiana De Cardiologia, 2020, 27, 4-6.	0.0	0
166	CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. Cardiovascular Drugs and Therapy, 2020, 34, 763-772.	4.1	10
167	Dual Pathway Inhibition for Vascular Protection in Patients With Atherosclerotic Disease: Rationale and Review of the Evidence. Thrombosis and Haemostasis, 2020, 120, 1147-1158.	4.6	32
168	Risk of Major Bleeding Among Users of Direct Oral Anticoagulants Combined With Interacting Drugs: A Population-Based Nested Case–Control Study. British Journal of Clinical Pharmacology, 2020, 86, 1150-1164.	3.0	65
169	New Opportunities for Improving the Prognosis of Patients With Chronic Ischemic Heart Disease. Rational Pharmacotherapy in Cardiology, 2020, 15, 873-880.	0.6	0
170	Causes and Secondary Prevention of Acute Ischemic Stroke in Adults. Hamostaseologie, 2020, 40, 022-030.	1.5	31
171	Intracranial Atherosclerosis Treatment. Stroke, 2020, 51, e49-e53.	9.1	63
172	Dual-Pathway Inhibition for Secondary and Tertiary Antithrombotic Prevention in Cardiovascular Disease. Nature Reviews Cardiology, 2020, 17, 242-257.	62.4	121
173	Tackling Elevated Risk in PAD: Focus on Antithrombotic and Lipid Therapy for PAD. Current Cardiology Reports, 2020, 22, 1-18.	4.5	3
174	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open, 2020, 2, 402-415.	1.8	8
175	Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease. Cardiovascular Drugs and Therapy, 2020, 34, 335-344.	4.1	7
176	Effect of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Heart Failure Patients With Atrial Fibrillation. Heart Failure Reviews, 2021, 26, 1391-1397.	6.2	5
177	The Role of Clopidogrel in 2020: A Reappraisal. Cardiovascular Therapeutics, 2020, 2020, 8703627.	3.0	87
178	Rivaroxaban Plus Aspirin for the Prevention of Ischaemic Events in Patients With Cardiovascular Disease: A Cost-Effectiveness Study. European Journal of Preventive Cardiology, 2020, 27, 1354-1365.	6.1	14
179	Cost-Effectiveness of Rivaroxaban Plus Aspirin (Dual Pathway Inhibition) for Prevention of Ischaemic Events in Patients With Cardiovascular Disease: On Top Optimisation of Secondary Prevention Medication in the Context of COVID-19 Pandemia. European Journal of Preventive Cardiology, 2020, 27, 1351-1353.	6.1	4
180	Potential Drug-Drug Interactions in Patients With Indication for Prophylactic Implantation of a Cardioverter Defibrillator: A Cross-Sectional Analysis. BMC Health Services Research, 2020, 20, 1-8.	3.8	3

#	Article	IF	Citations
181	Equipoise in Management of Patients With Acute Symptomatic Carotid Stenosis (Hot Carotid). Neurology: Clinical Practice, 2021, 11, 25-32.	3.2	6
182	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. Circulation, 2020, 141, e779-e806.	24.6	285
183	Efficacy and Safety of Low Dose Rivaroxaban in Patients With Coronary Heart Disease: A Systematic Review and Meta-Analysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 913-920.	2.2	20
184	EUROASPIRE V and Uncontrolled Risk Factors in Primary Prevention: Atherosclerotic Cardiovascular Disease in the Making. European Journal of Preventive Cardiology, 2021, 28, 380-382.	6.1	14
185	Efficacy and Safety of Rivaroxaban Plus Aspirin in Women and Men With Chronic Coronary or Peripheral Artery Disease. Cardiovascular Research, 2021, 117, 942-949.	13.5	24
186	The Role of Rivaroxaban for Patients With Atherosclerotic Vascular Disease in the Modern Era. Catheterization and Cardiovascular Interventions, 2021, 97, 1221-1229.	2.2	1
187	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	12.0	17
188	Benefit and Risk of Adding Rivaroxaban in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis. Clinical Cardiology, 2021, 44, 20-26.	3.1	8
189	Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned From the Literature. Thrombosis and Haemostasis, 2021, 121, 553-564.	4.6	41
190	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care, 2021, 44, S125-S150.	20.9	475
191	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	2.4	5
192	2020 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. European Heart Journal, 2021, 42, 1289-1367.	14.7	4,598
193	Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights From the Veterans Affairs Healthcare System. Cardiovascular Drugs and Therapy, 2021, 35, 533-538.	4.1	2
194	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Versus Aspirin Alone in Secondary Prevention Among Patients With Chronic Cardiovascular Diseases. Cardiovascular Drugs and Therapy, 2021, 35, 539-547.	4.1	8
195	Outcomes of Anticoagulant Therapy With Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO). Current Vascular Pharmacology, 2021, 19, 655-662.	2.4	12
196	Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. Heart International, 2021, 15, 14-19.	2.6	2
197	Clopidogrel Versus Ticagrelor in Elective Percutaneous Coronary Intervention. Journal of Advanced Pharmacy Education and Research, 2022, 12, 30-37.	1.9	3
198	Атеросклеротические сердечно-сосудистые заболевания и сахарный диабет 2-го типа. Как учесть все нюансы в выборе терапии?. Kardiologiya, 2021, 61, 78-86.	0.9	3

#	Article	IF	Citations
199	Medical Therapy for Cardiovascular and Limb-Related Risk Reduction in Critical Limb Ischemia. Vascular Medicine, 2021, 26, 210-224.	2.3	8
200	Factors Associated With Infrainguinal Bypass Graft Patency at 1-Year; A Retrospective Analysis of a Single Centre Experience. Perfusion (United Kingdom), 2022, 37, 276-283.	1.8	5
201	A Narrative Review of Low-Dose Rivaroxaban in Patients With Atherothrombotic Cardiovascular Disease: Vascular Protection Beyond Anticoagulation. Cardiovascular Diagnosis and Therapy, 2021, 11, 13041-13141.	2.1	10
202	New Cardiovascular Prevention Guidelines: How to Optimally Manage Dyslipidaemia and Cardiovascular Risk in 2021 in Patients Needing Secondary Prevention?. Atherosclerosis, 2021, 319, 51-61.	7.0	77
203	Primary Prophylaxis of Venous Thromboembolic Disease With Direct Oral Anticoagulants in Patients With Severe Inherited Thrombophilia. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 261-264.	3.3	3
204	Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 11, 608247.	5.3	9
205	Особенности антитромботической терапии у пациентов с мультифокальным поражением артерий. Kardiologiya, 2021, 61, 87-95.	0.9	0
206	The Efficacy and Safety of Direct Oral Anticoagulants Plus Aspirin in Symptomatic Lower Extremity Peripheral Arterial Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Thrombosis and Thrombolysis, 2021, 52, 904-913.	2.2	6
207	Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e019184.	5.8	16
208	Aortic Valvular Stenosis: Novel Therapeutic Strategies. European Journal of Clinical Investigation, 2021, 51, e13527.	4.4	12
209	Life and Limb Protection With Dual Anti-Thrombotic Pathway Inhibition: COMPASS Ushers in a New Day in Atherothrombotic Risk Reduction. Med, 2021, 2, 233-242.	12.3	4
210	Prevalence of Diabetes and Impact on Cardiovascular Events and Mortality in Patients With Chronic Coronary Syndromes, Across Multiple Geographical Regions and Ethnicities. European Journal of Preventive Cardiology, 2022, 28, 1795-1806.	6.1	37
211	Dual Therapy With an Oral Non-Vitamin K Antagonist and a P2Y12 Inhibitor vs Triple Therapy With Aspirin, a P2Y12 Inhibitor and a Vitamin K Antagonist for the Treatment of Diabetes Mellitus Patients With Co-Existing Atrial Fibrillation Following Percutaneous Coronary Intervention: A Meta-Analysis. Medicine (United States), 2021, 100, e25546.	2.1	2
212	Clinical Considerations After Endovascular Therapy of Peripheral Artery Disease. Expert Review of Cardiovascular Therapy, 2021, 19, 369-378.	2.7	2
213	Gene Expression Signature in Patients With Symptomatic Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 1521-1533.	7.9	22
214	Antithrombotic Therapy for Stroke Patients With Cardiovascular Disease. Seminars in Neurology, 2021, 41, 365-387.	2.4	3
215	Diagnosis and Management of Stable Angina: A Review. JAMA - Journal of the American Medical Association, 2021, 325, 1765-1778.	37.0	118
216	Efficacy and Safety of Rivaroxaban Therapy for Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Vascular and Endovascular Surgery, 2021, 55, 712-720.	0.9	5

#	Article	IF	Citations
217	Features of Risk Stratification, Diagnosis and Secondary Prevention in Patients With Multifocal Arterial Disease. Part 2: Treatment Options. Rational Pharmacotherapy in Cardiology, 2021, 17, 239-248.	0.6	0
218	Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The Role of the COMPASS Strategy. Current Cardiology Reviews, 2021, 17, 294-305.	2.9	4
219	Considerations for Use of Direct Oral Anticoagulants in Arterial Disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12502.	3.3	3
220	Diabetes Mellitus Was Not Associated With Lower Amputation-Free Survival After Open Revascularization for Chronic Limb-Threatening Ischemia – A Nationwide Propensity Score Adjusted Analysis. Vascular Medicine, 2021, 26, 507-514.	2.3	7
221	Cardiovascular Consequences of Discontinuing Low-Dose Rivaroxaban in People With Chronic Coronary or Peripheral Artery Disease. Heart, 2021, 107, 1130-1137.	4.9	11
222	Prognostic Value of D-Dimer in Patients With Acute Coronary Syndrome Treated by Percutaneous Coronary Intervention: A Retrospective Cohort Study. Thrombosis Journal, 2021, 19, 1-11.	2.9	20
223	Профилактика сердечно-сосудистых событий у пациентов со стабильной ишемической болезнью сердца: реваскуляризация миокарда или медикаментозная терапия?. Cardiovascular Therapy and Prevention (Russian Federation), 2021, 20, 2888.	1.4	1
224	MiR-126-3p and MiR-223-3p as Biomarkers for Prediction of Thrombotic Risk in Patients With Acute Myocardial Infarction and Primary Angioplasty. Journal of Personalized Medicine, 2021, 11, 508.	3.9	33
225	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-Risk Chronic Coronary Syndrome. European Cardiology Review, 2021, 16, e26.	2.4	13
226	Many Good Reasons to Switch From Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients With Non-Valvular Atrial Fibrillation. Journal of Clinical Medicine, 2021, 10, 2866.	3.8	9
227	Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome. American Journal of Cardiology, 2021, 148, 1-7.	2.4	6
228	Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento del síndrome coronario agudo (SCA) en pacientes sin elevación persistente del segmento ST. Revista Espanola De Cardiologia, 2021, 74, 544.e1-544.e73.	0.4	26
229	Cardiovascular Risk Management in Type 2 Diabetes Mellitus: A Joint Position Paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	4.0	5
230	Peripheral Artery Disease in Germany (2009–2018): Prevalence, Frequency of Specialized Ambulatory Care and Use of Guideline-Recommended Therapy – A Population-Based Study. Lancet Regional Health - Europe, The, 2021, 5, 100113.	13.5	47
231	Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circulation Research, 2021, 128, 1818-1832.	15.7	594
232	Реестр пациентов с острым коронарным синдромом и фибрилляцией предсердий, принимающих ривароксабан. Результаты наблюдения. Kardiologiya, 2021, 61, 52-58.	0.9	0
233	Fibrin Clot Properties in Atherosclerotic Vascular Disease: From Pathophysiology to Clinical Outcomes. Journal of Clinical Medicine, 2021, 10, 2999.	3.8	43
234	Continuation Versus Interruption of Direct Oral Anticoagulants for CIED Procedures: New Anticoagulants, Old Dilemma. Case Reports, 2021, 3, 1141-1144.	0.7	1

#	Article	IF	Citations
235	Latin American Consensus on Management of Residual Cardiometabolic Risk. A Consensus Paper Prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) Endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Archivos De Cardiologia De Mexico, 2022, 92, 99-112.	0.2	15
236	Prophylactic Anticoagulation in Sinus Rhythm for Stroke Prevention in Cardiovascular Disease: Contemporary Meta-Analysis of Large Randomized Trials. European Journal of Preventive Cardiology, 2022, 28, 1939-1948.	6.1	1
237	Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST – 2021. Arquivos Brasileiros De Cardiologia, 2021, 117, 181-264.	1.2	82
238	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	12.0	52
239	Outcomes After Receipt of Neuraxial or Regional Anesthesia Instead of General Anesthesia for Lower Limb Revascularization Surgery: Protocol for a Systematic Review and Meta-Analysis. JMIR Research Protocols, 2021, 10, e32170.	1.8	3
240	Antithrombotic Treatment for Peripheral Arterial Occlusive Disease. Deutsches Ärzteblatt International, 2021, 118, 528-535.	3.5	7
241	Updated Antithrombotic Strategies to Reduce the Burden of Cardiovascular Recurrences in Patients With Chronic Coronary Syndrome. Biomedicine and Pharmacotherapy, 2021, 140, 111783.	9.8	3
242	Efficacy and Safety of Antiplatelet Therapies in Symptomatic Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Current Vascular Pharmacology, 2021, 19, 542-555.	2.4	25
243	Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus. , 2021, .		18
244	Mechanisms, Prevention and Treatment of Saphenous Vein Graft Disease. American Journal of Cardiology, 2021, 154, 41-47.	2.4	8
245	Evidence-Based Medical Management of Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 541-553.	7.9	191
246	Is There a Role for Low-Dose DOACs as Prophylaxis?. Hematology, 2019, 2019, 187-193.	2.5	6
247	C-Reactive Protein and All-Cause Mortality in Patients With Stable Coronary Artery Disease: A Secondary Analysis Based on a Retrospective Cohort Study. Medical Science Monitor, 2019, 25, 9820-9828.	2.4	8
248	Direct-Acting Anticoagulants in Chronic Coronary Syndromes. European Cardiology Review, 2019, 15, 1-7.	2.4	4
249	2020 Clinical Practice Guidelines for Acute ST-Segment Elevation Myocardial Infarction. Russian Journal of Cardiology, 2020, 25, 4103.	1.9	206
250	Лечение пациентов со стабильными проявлениями атеросклероза: новые возможности (Заключение совета экспертов от 16 ноября 2018 г., г. Ростов-на-Дону). Kardiologiya, 2019, 59, 97-100.	0.9	3
251	Выбор и классификация лекарственных препаратов при коморбидных заболеваниях. Russian Archives of Internal Medicine, 2020, 10, 57-60.	0.4	2
252	Apixaban Versus No Anticoagulation in Patients Undergoing Long-Term Dialysis With Incident Atrial Fibrillation. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1146-1154.	5.8	98

#	Article	IF	Citations
253	Non-Vitamin K Oral Anticoagulants for Coronary or Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Mortality and Major Bleeding. Minerva Cardioangiologica, 2019, 67, 477-486.	1.1	6
254	Therapeutic Aspects of the Choice of Antithrombotic Therapy in Patients With Multifocal Lesions of Peripheral Arteries. Terapevticheskii Arkhiv, 2019, 91, 158-164.	0.9	3
255	Ways of Decreasing Incidence of Complications in Patients After Endured Reconstructive and Endovascular Operations on Lower Limb Arteries. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2020, 26, 165-173.	0.2	2
256	Another Unmet Need Against Residual Risk of Atherosclerotic Cardiovascular Disease: Can "Thrombin Pathway" Be a New Target for Therapy?. Korean Circulation Journal, 2020, 50, 817-821.	1.7	5
257	Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report From the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee. Journal of Atherosclerosis and Thrombosis, 2020, 27, 809-907.	3.7	78
258	Prolonged Antithrombotic Therapy in Patients After Acute Coronary Syndrome: A Critical Appraisal of Current European Society of Cardiology Guidelines. Cardiology Journal, 2020, 27, 661-676.	1.7	11
259	An Evaluation of Rivaroxaban and Clopidogrel in a Rat Lower Extremity Ischemia-Reperfusion Model: An Experimental Study. Turkish Journal of Thoracic and Cardiovascular Surgery, 2019, 27, 513-520.	0.5	10
260	Reducing Residual Thrombotic Risk in Patients With Peripheral Artery Disease: Impact of the COMPASS Trial. Drugs in Context, 2020, 9, 1-15.	2.5	6
261	Contemporary Coronary Artery Bypass Graft Surgery and Subsequent Percutaneous Revascularization. Nature Reviews Cardiology, 2022, 19, 195-208.	62.4	83
262	COVID-19 Vaccine-Induced Immune Thrombosis With Thrombocytopenia (VITT) and the Shades of Grey in Thrombus Formation. Seminars in Thrombosis and Hemostasis, 2022, 48, 015-018.	4.1	4
263	Combination Anticoagulant or P2Y12 Inhibitor With Low-Dose Aspirin Versus Low-Dose Aspirin Alone in Patients at Risk or With Documented Coronary And/Or Peripheral Artery Disease. Current Medical Research and Opinion, 2022, 38, 27-34.	2.9	2
264	Medical Management of Peripheral Artery Disease. Cardiology Clinics, 2021, 39, 471-482.	1.4	9
265	Rivaroxaban Clinical Trials in 2018: Successes, Failures, and Lessons Learned. The Hematologist, 2019, .	0.2	0
266	PAVK der unteren Extremitäten – konservative und antithrombotische Therapie. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2018, 05, 277-293.	0.0	0
267	Vascular Investigation and Therapy. Vascular Investigation and Therapy, 2019, 2, 55.	0.2	1
268	Coronary Artery Motion Tracking Using Landmark Guided Point Set Registration. , 2019, .		0
269	Sekundární prevence ischemické choroby srdeční a onemocnění periferních tepen kombinací antiagregační a antikoagulační léčby.Odborné stanovisko České kardiologické společnosti, České internistické společnosti a České angiologické společnosti k výsledkům studie COMPASS. Cor Et Vasa, 2019, 61, e334-e340.	0.3	0
270	Efficacy and Safety of Antiplatelet Therapy Plus Xa Factor Inhibitors in Patients With Coronary Heart Disease: A Meta-Analysis. Medical Science Monitor, 2019, 25, 5473-5481.	2.4	2

#	Article	IF	Citations
271	Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism Beyond Atrial Fibrillation. Journal of Stroke, 2019, 21, 259-275.	7.6	7
272	Место ривароксабана в лечении пациентов со стабильными формами ишемической болезни сердца. Meditsinskiy Sovet, 2019, 0, 34-41.	0.4	0
273	Sekundární prevence ischemické choroby srdeční a chorob periferních tepen kombinací antiagregační a antikoagulační léčby. Odborné stanovisko České kardiologické společnosti, České internistické společnosti ČLS J.E. Purkyně a České angiologické společnosti ČLS J.E. Purkyně k výsledkům studie COMPASS. Vnitrni Lekarstvi, 2019, 65, 704-710.	0.2	0
274	Фармакоэкономическое исследование применения комбинированной терапии ривароксабаном с ацетилсалициловой кислотой у пациентов с ишемической болезнью сердца и/или заболеванием периферических артерий. Russian Journal of Cardiology, 2019, 0, 76-86.	1.9	2
275	Emerging Clinical Setting of Direct Oral Anticoagulants: Atherothrombotic Events Prevention. Journal of Cardiovascular Medicine, 2020, 21, 1.	2.3	3
276	Rivaroxaban Ve Studii COMPASS. Vnitrni Lekarstvi, 2020, 66, 197-198.	0.2	1
277	Prodlužování agresivní antitrombotické léčby po infarktu myokardu: proč, komu a jakou léčbu vybrat?. Vnitrni Lekarstvi, 2020, 66, 160-168.	0.2	0
278	Choosing Antithrombotic Therapy in Patients With Coronary Heart Disease and Type 2 Diabetes Mellitus: How to Reduce the Risk of Death. Kardiologiya, 2020, 60, 109-119.	0.9	1
279	Management of Ischemic Risk Events in Patients With Multifocal Atherosclerosis and Type 2 Diabetes Mellitus. Atherothrombosis, 2020, .	0.5	1
280	Residual Risk Reduction Opportunities in Patients With Chronic Coronary Syndrome. Role of Dual Pathway Inhibition. Expert Review of Clinical Pharmacology, 2020, 13, 695-706.	3.6	6
281	Recent Advances in Preventing Recurrent Stroke. F1000Research, 2020, 9, 1012.	1.1	1
282	Влияние низких доз ривароксабана на клинические проявления стабильной стенокардии II–III функционального класса и качество жизни больных ишемической болезнью сердца. Kardiologiya, 2021, 61, 47-51.	0.9	2
283	Antithrombotic Therapy for Chronic Ischemic Heart Disease: How to Balance Risk and Benefit in Different Categories of Patients?. Atherothrombosis, 2020, .	0.5	0
284	Highlights From the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention. Ecancermedicalscience, 2020, 14, 998.	1.6	5
285	Prospects of Rivaroxaban Application in Treatment of Patients With Chronic Ischemic Heart Disease. Meditsinskiy Sovet, 2020, 0, 44-50.	0.4	0
286	Combined Antithrombotic Therapy in Patients With a Stable Atherosclerotic Cardiovascular Diseases: What Direction Did COMPASS Show?. Kardiologiya, 2020, 60, 131-141.	0.9	0
287	Principal Predictors of Major Adverse Limb Events in Diabetic Peripheral Artery Disease: A Narrative Review. Atherosclerosis Plus, 2021, 46, 1-14.	2.5	15
288	Long-Term Pharmacological Management of Reduced Ejection Fraction Following Acute Myocardial Infarction: Current Status and Future Prospects. International Journal of General Medicine, 2021, 14, 7797-7805.	2.5	5

#	Article	IF	Citations
289	Coronary Artery Disease With a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?. Rational Pharmacotherapy in Cardiology, 2020, 16, 465-473.	0.6	0
290	Тикагрелор и его роль в улучшении прогноза у пациентов со стабильной ишемической болезнью сердца. Russian Journal of Cardiology, 2020, 25, 4094.	1.9	0
291	Vascular Diseases: Atherosclerosis and Atherosclerotic Cardiovascular Diseases. , 2022, .		1
292	High Perceived Stress May Shorten Activated Partial Thromboplastin Time and Lead to Worse Clinical Outcomes in Patients With Coronary Heart Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 769857.	3.2	18
293	Arzneiverordnungs-Report 2021. , 2021, .		51
294	Update on the Pathophysiology and Medical Treatment of Peripheral Artery Disease. Nature Reviews Cardiology, 2022, 19, 456-474.	62.4	217
295	Minding the Gap – Heterogeneity of Antithrombotic Treatment Preferences in Complex Scenarios in Absence of Evidence-Based Guidelines. International Journal of Cardiology, 2022, 348, 83-84.	3.2	0
296	Acetylsalicylsäure: Heutiger Stellenwert in der antithrombotischen Therapie. , 2019, .		0
297	Herzinfarkt: Was Kommt in Den Jahren Danach?. , 2019, .		2
298	Newer Oral Anticoagulant Therapy – Prospects and Practices: A Review. Indian Journal of Pharmacy Practice, 2020, 13, 215-221.	1.0	1
299	Long-Term Outcomes of Coronary Artery Bypass Graft Surgery in Patients With Widespread Atherosclerotic Lesions of the Coronary and Peripheral Vascular Basins (Based on the REGATA Long-Term Antithrombotic Therapy Registry). Atherothrombosis, 2022, 11, 30-43.	0.5	5
300	Pharmacodynamic Profiles of Dual-Pathway Inhibition With or Without Clopidogrel Versus Dual Antiplatelet Therapy in Patients With Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351.	4.6	21
301	Atherosclerosis and Atrial Fibrillation: Double Trouble. Current Cardiology Reports, 2022, 24, 67-73.	4.5	13
302	Rivaroxaban With Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial. Clinical and Applied Thrombosis/Hemostasis, 2022, 28, 10760296211073922.	2.2	5
303	Choice of Antithrombotic Therapy for Patients With Atrial Fibrillation Undergoing Carotid Angioplasty and Stenting: A Nationwide Population-Based Study. Scientific Reports, 2022, 12, 1-9.	5.2	11
304	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, e722-e759.	24.6	627
305	Women Specific Characteristics and 1-Year Outcome Among Patients Hospitalized for Peripheral Artery Disease: A Monocentric Cohort Analysis in a Tertiary Center. Frontiers in Cardiovascular Medicine, 2022, 9, 824466.	3.2	7
306	Prognostic Value of Age-Adjusted D-Dimer Cutoff Thresholds in Patients With Acute Coronary Syndrome Treated by Percutaneous Coronary Intervention. Clinical Interventions in Aging, 2022, 17, 117-128.	4.2	5

#	Article	IF	Citations
307	Effect of Combining Aspirin and Rivaroxaban on Atherosclerosis in Mice. Atherosclerosis, 2022, 345, 7-14.	7.0	8
308	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care, 2022, 45, S144-S174.	20.9	500
309	Dual Pathway of Inhibition and Vascular Protection in Patients With Atherosclerotic Disease. , 2021, .		0
310	Modern Strategies of Antithrombotic Therapy in Patients With Multifocal Atherosclerosis. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 49-55.	0.9	0
311	Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA - Journal of the American Medical Association, 2022, 327, 662-675.	37.0	769
312	Akutes Koronarsyndrom: Risikostratifizierung und Therapie. Intensivmedizin Up2date, 2022, 18, 81-109.	0.0	0
313	Sex Differences in Peripheral Artery Disease. Circulation Research, 2022, 130, 496-511.	15.7	190
314	Treatment Standards for Direct Oral Anticoagulants in Patients With Acute Ischemic Stroke and Non-Valvular Atrial Fibrillation: A Survey Among German Stroke Units. PLoS ONE, 2022, 17, e0264122.	3.2	9
315	Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus After Anterior ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2022, 15, 861-872.	5.0	52
316	Cardiovascular Efficacy of Liraglutide and Semaglutide in Individuals With Diabetes and Peripheral Artery Disease. Diabetes, Obesity and Metabolism, 2022, 24, 1288-1299.	6.0	60
317	Reasoning Is to Be Welcomed. Deutsches Ärzteblatt International, 2022, 119, 197.	3.5	0
318	Circulating Biomarkers in Lower Extremity Artery Disease. European Cardiology Review, 2022, 17, e09.	2.4	15
319	Endothelial Dysfunction in the Pathogenesis of Abdominal Aortic Aneurysm. Biomolecules, 2022, 12, 509.	5.8	77
320	DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm. Current Atherosclerosis Reports, 2022, 24, 457-469.	7.3	4
321	Long-Term Treatment With the Combination of Rivaroxaban and Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS Trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	5.0	20
322	Towards Personalized Therapy of Aortic Stenosis. Journal of Personalized Medicine, 2021, 11, 1292.	3.9	10
323	Practical Importance of COMPASS Trial Results for Vascular Surgeons. , 2020, .		0
324	Advances in Recurrent Stroke Prevention: Focus on Antithrombotic Therapies. Circulation Research, 2022, 130, 1075-1094.	15.7	28

#	Article	IF	Citations
325	Major Adverse Limb Events in Patients With Femoro-Popliteal and Below-the-Knee Peripheral Arterial Disease Treated With Either Sirolimus-Coated Balloon or Standard Uncoated Balloon Angioplasty: A Structured Protocol Summary of the "SirPAD" Randomized Controlled Trial. Trials, 2022, 23, 1-15.	2.6	8
326	Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants: Navigating the Choice of Oral Anticoagulant Drugs in the COVID-19 Pandemic Era. Cardiology Plus, 2020, 5, 171.	1.7	0
327	COMPASS Study Results as a Foundation for New Treatment Approach for Neurological Patients. Opinion of the Expert Council of December 18, 2021. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 94-99.	0.9	2
328	Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines. Frontiers in Pharmacology, 2022, 13, 878416.	5.3	6
329	Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench. Frontiers in Cardiovascular Medicine, 2022, 9, 826478.	3.2	9
330	European Stroke Organisation (ESO) Guideline on Pharmacological Interventions for Long-Term Secondary Prevention After Ischaemic Stroke or Transient Ischaemic Attack. European Stroke Journal, 2022, 7, I-II.	5.8	227
331	Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study. Frontiers in Cardiovascular Medicine, 2022, 9, 865166.	3.2	5
332	Coagulation Factors XI and XII as Possible Targets for Anticoagulant Therapy. Thrombosis Research, 2022, 214, 53-62.	2.9	25
333	Interventional Cardiology. , 2022, .		252
334	Clinical Experience With Dual Pathway Inhibition Therapy: Case Series and Mini Review. European Heart Journal - Case Reports, 2022, 6, ytac201.	0.6	1
335	Clinical Opportunities and Healthcare Impact of Optimal Treatment in the Post-ACS Patient. Global & Regional Health Technology Assessment, 2022, 9, 17-26.	0.8	1
336	Patients Selected for Dual Pathway Inhibition in Clinical Practice Have Similar Characteristics and Outcomes to Those Included in the COMPASS Randomized Trial: The XATOA Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 825-836.	5.0	29
337	Atherosclerotic Plaque Composition and Specific Endovascular Considerations in the End Stage Renal Disease Patients: A Narrative Review. Cardiovascular Diagnosis and Therapy, 2023, 13, 13346-13146.	2.1	3
338	Efficacy and Safety of New Oral Anticoagulants Combined With Antiplatelet Drugs in the Treatment of Coronary Heart Disease: Systematic Evaluation and Meta-Analysis. Annals of Noninvasive Electrocardiology, 2022, 27, e12977.	0.9	3
339	Axial Ablation Versus Terminal Interruption of the Reflux Source (AAVTIRS): A Randomised Controlled Trial. Trials, 2022, 23, 1-10.	2.6	1
340	Clinical Evaluation of the Automatic Coronary Artery Disease Reporting and Data System (CAD-RADS) in Coronary Computed Tomography Angiography Using Convolutional Neural Networks. Academic Radiology, 2023, 30, 698-706.	4.3	31
341	Extra-Cranial Carotid Artery Stenosis: An Objective Analysis of the Available Evidence. Frontiers in Neurology, 2022, 13, 739999.	3.5	29
342	Potential Reduction in Adverse Events and Cost With Novel Anticoagulants Among Patients With Acute Limb Ischemia. International Journal of Vascular Medicine, 2022, 2022, 3786815.	1.0	1

#	Article	IF	Citations
343	Clinical Outcomes After Endovascular Revascularisation of the Femoropopliteal Arterial Segment in Patients With Anticoagulant Versus Antiplatelet Therapy: A Single-Centre Retrospective Cohort Study. Journal of Cardiovascular Development and Disease, 2022, 9, 207.	2.9	1
344	Rivaroxaban and Aspirin vs. Aspirin Alone in Asian Compared With Non-Asian Patients With Chronic Coronary Artery Disease or Peripheral Arterial Disease: The COMPASS Trial. European Heart Journal, 2022, 43, 3542-3552.	14.7	15
345	Australian Guideline on Diagnosis and Management of Peripheral Artery Disease: Part of the 2021 Australian Evidence-Based Guidelines for Diabetes-Related Foot Disease. Journal of Foot and Ankle Research, 2022, 15, 1-25.	2.7	27
346	Outcomes of Hospitalized Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) With and Without a History of Peripheral Artery Disease. Cureus, 2022, 14, e26585.	1.3	0
347	Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review. Advanced Pharmaceutical Bulletin, 2023, 13, 259-268.	3.7	11
348	Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy. Drugs, 2022, 82, 1165-1177.	15.5	14
349	Influence of Concomitant Percutaneous Transluminal Angioplasty With Percutaneous Coronary Intervention on Clinical Outcomes of Stable Lower Extremity Artery Diseases. Scientific Reports, 2022, 12, 1-11.	5.2	3
350	Managing Thrombotic Risk in Patients With Diabetes. Cardiovascular Diabetology, 2022, 21, 1-16.	15.7	19
351	Thromboinflammation in Cardiovascular Disease: Lessons Learned for the Management of Hypertension, Heart Failure, and Aortic Valve Stenosis. European Heart Journal, 2022, 43, 4611-4613.	14.7	3
352	Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs, 2022, 82, 1287-1302.	15.5	33
353	Nachsorge der Patienten nach infarktbedingtem kardiogenem Schock. Deutsche Medizinische Wochenschrift, 2022, 147, 1187-1194.	0.3	0
354	Cellular Senescence and Cardiovascular Diseases: Moving to the “Heart” of the Problem. Physiological Reviews, 2023, 103, 609-647.	35.9	119
355	Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials. International Journal of General Medicine, 2022, 15, 7201-7208.	2.5	8
356	Comparative Efficacy and Safety of Antiplatelet or Anticoagulant Therapy in Patients With Chronic Coronary Syndromes After Percutaneous Coronary Intervention: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology, 2022, 13, 992376.	5.3	8
357	Emerging Roles of Protease-Activated Receptors in Cardiometabolic Disorders. Journal of Cardiology, 2023, 81, 337-346.	3.8	14
358	Dual Pathway Inhibition as Compared to Acetylsalicylic Acid Monotherapy in Relation to Endothelial Function in Peripheral Artery Disease, a Phase IV Clinical Trial. Frontiers in Cardiovascular Medicine, 2022, 9, 979819.	3.2	3
359	Antithrombotic Strategy in Secondary Prevention for High-Risk Patients With Previous Acute Coronary Syndrome: Overlap Between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry. American Journal of Cardiovascular Drugs, 2023, 23, 77-87.	3.7	4
360	Preoperative Evaluation and Perioperative Management of Patients Undergoing Major Vascular Surgery. Vascular Medicine, 2022, 27, 496-512.	2.3	36

#	Article	IF	Citations
361	Antithrombotic Therapy in Peripheral Arterial Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 927645.	3.2	10
362	Platelet–Neutrophil Interaction and Thromboinflammation in Diabetes: Considerations for Novel Therapeutic Approaches. Journal of the American Heart Association, 2022, 11, e027071.	5.8	41
363	Inflammatory and Prothrombotic Biomarkers, DNA Polymorphisms, MicroRNAs and Personalized Medicine for Patients With Peripheral Arterial Disease. International Journal of Molecular Sciences, 2022, 23, 12054.	5.9	21
364	Cost-Effectiveness Analysis of Screening for Peripheral Artery Disease in Patients With Coronary Artery Disease in China: A Markov Model. International Journal of Cardiology, 2023, 371, 420-426.	3.2	0
365	Long-Term Management of Patients With Myocardial Infarction: An Updated Review. Cardiology Discovery, 2022, 2, 241.	0.6	9
366	Endothelial Cell Dysfunction: Implications for the Pathogenesis of Peripheral Artery Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 1054576.	3.2	51
367	Defining Preventive Cardiology: A Clinical Practice Statement From the American Society for Preventive Cardiology. American Journal of Preventive Cardiology, 2022, 12, 100432.	5.0	45
368	Non-Vitamin K Antagonist Oral Anticoagulants for COVID-19 Thrombosis. Journal of Acute Disease, 2022, 11, 212-221.	0.5	0
369	Le patient atteint de maladies cardiovasculaires: Insuffisance coronarienne, insuffisance cardiaque, troubles du rythme, thrombose. , 2022, .		0
370	Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events: A Secondary Analysis of the COMPASS Trial. JAMA Network Open, 2022, 5, e2243201-e2243201.	10.2	15
371	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023. Diabetes Care, 2023, 46, S158-S190.	20.9	464
372	Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice—Insights From the CANHEART Study. Journal of the American Heart Association, 2022, 11, e026553.	5.8	3
373	Role of Cerebral Microbleeds in Acute Ischemic Stroke and Atrial Fibrillation. Journal of Thrombosis and Thrombolysis, 2023, 55, 553-565.	2.2	1
374	Diabetic Foot Ulcer: Challenges and Future. World Journal of Diabetes, 2022, 13, 1014-1034.	4.4	145
375	Long-Term Prognostic Impact of Sex in Patients With Chronic Coronary Syndrome: A 17-Year Prospective Cohort Study. Journal of Women's Health, 2023, 32, 63-70.	2.1	2
376	Risk Scores for Predicting Incident Heart Failure Admission in Patients With Chronic Coronary Syndromes: Validation in a Prospective, Monocentric, Long-Term, Cohort Study. European Journal of Clinical Investigation, 2023, 53, e13941.	4.4	0
377	Association of Lipoprotein(a) Levels With Incidence of Major Adverse Limb Events. JAMA Network Open, 2022, 5, e2245720-e2245720.	10.2	30
378	Dual Pathway Inhibition in Patients With Atherosclerotic Disease: Pharmacodynamic Considerations and Clinical Implications. Expert Review of Clinical Pharmacology, 2023, 16, 27-38.	3.6	18

#	Article	IF	Citations
379	Inadequate Response to Antiplatelet Therapy in Patients With Peripheral Artery Disease: A Prospective Cohort Study. Thrombosis Journal, 2023, 21, 1-10.	2.9	8
380	Efficacy and Safety Outcomes of Long-Term Anti-Thrombotic Treatment of Chronic Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2023, 9, 1016390.	3.2	0
381	Antithrombotic Therapy in Patients With Diabetes Mellitus. Vestnik of Russian Military Medical Academy, 2023, 24, 737-750.	0.3	2
382	Secondary Prevention of Antithrombotic Therapy in Patients With Stable Cardiovascular Disease at High Ischemic Risk: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2023, 9, 1040473.	3.2	4
383	Cardiovascular Disease Management in the Context of Global Crisis. International Journal of Environmental Research and Public Health, 2023, 20, 689.	4.2	9
384	Сахарный диабет 2 типа и микрососудистые осложнения у больных стабильной ишемической болезнью сердца: распространенность, прогноз и выбор антитромботической терапии. Ûžno-Rossijskij žurnal Terapevtičeskoj Praktiki, 2022, 3, 7-24.	0.3	4
385	Catheter-Directed Thrombolysis for Persistent Sciatic Artery Presenting With Acute Limb Ischemia. Vascular Specialist International, 2022, 38, 44.	1.3	2
386	Advances in the Available Pharmacotherapy for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation. Expert Opinion on Pharmacotherapy, 2023, 24, 453-471.	3.5	17
387	Arzneiverordnungs-Report 2022. , 2022, .		60
388	Chinese Expert Consensus on Antithrombotic Management of High-Risk Elderly Patients With Chronic Coronary Syndrome. Aging Medicine (Milton (N S W)), 2023, 6, 4-24.	3.2	4
389	Guideline-Directed Medical Therapy and Long-Term Mortality and Amputation Outcomes in Patients Undergoing Peripheral Vascular Interventions. JACC: Cardiovascular Interventions, 2023, 16, 332-343.	5.0	28
390	Clinical Evaluation of Factor XIa Inhibitor Drugs: JACC Review Topic of the Week. Journal of the American College of Cardiology, 2023, 81, 771-779.	12.0	81
391	Early Identification and Treatment for Peripheral Arterial Disease in Patients With Ischemic Cerebrovascular Disease. European Journal of Medical Research, 2023, 28, 1-7.	5.0	8
392	Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients With Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. American Journal of Cardiovascular Drugs, 2023, 23, 257-267.	3.7	0
393	Management of Stable Angina: A Treatment Strategy Mnemonic. Journal for Nurse Practitioners, 2023, 19, 104473.	0.9	0
394	Antiplatelet Strategies Following PCI: A Review of Trials Informing Current and Future Therapies. Journal of the Society for Cardiovascular Angiography & Interventions, 2023, 2, 100607.	2.3	21
395	Real-World Racial Variation in Treatment and Outcomes Among Patients With Peripheral Artery Disease. Advances in Therapy, 2023, 40, 1850-1866.	5.0	14
396	The Role of Long Non-Coding RNA in Abdominal Aortic Aneurysm. Frontiers in Genetics, 2023, 14, 1153899.	3.2	13

#	Article	IF	Citations
397	Role of the Advanced Nurse Practitioner Within the Vascular Team: A Qualitative Study of Vascular Physicians and Nurses. Frontiers in Public Health, 2023, 11, 1070403.	4.3	9
398	Current Concepts and Novel Targets for Antiplatelet Therapy. Nature Reviews Cardiology, 2023, 20, 583-599.	62.4	132
399	Лечение пациентов с хронической ишемической болезнью сердца и сахарным диабетом 2 типа. Russian Archives of Internal Medicine, 2023, 13, 97-109.	0.4	2
400	Antithrombotic Regimens for the Prevention of Major Adverse Cardiac Events in Chronic Coronary Syndrome: A Systematic Review and Network Meta-Analysis. Frontiers in Cardiovascular Medicine, 2023, 10, 1040936.	3.2	6
401	Aspirin Microcrystals Deposited on High-Density Microneedle Tips for the Preparation of Soluble Polymer Microneedles. Drug Delivery and Translational Research, 2023, 13, 2639-2652.	7.6	12
402	Revascularization and Medical Therapy for Chronic Coronary Syndromes: Lessons Learnt From Recent Trials, a Literature Review. Journal of Clinical Medicine, 2023, 12, 2833.	3.8	19
403	Influence of an Abnormal Ankle-Brachial Index on Ischemic and Bleeding Events in Patients Undergoing Percutaneous Coronary Intervention. Korean Journal of Internal Medicine, 2023, 38, 372-381.	2.1	3
404	Optimization of the Pharmacological Therapy in Patients With Poly-Vascular Disease: A Multidisciplinary Approach. World Journal of Cardiology, 2023, 15, 142-153.	2.5	8
405	Dietary Intake and Cardiovascular Outcomes in Patients With Chronic Vascular Disease: Insights From the COMPASS Trial Cohort. European Journal of Preventive Cardiology, 2023, 30, 709-718.	6.1	16
406	Low Dose Rivaroxaban for the Management of Atherosclerotic Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2023, 56, 91-102.	2.2	9
407	Low-Dose Rivaroxaban: Can Cardiovascular Events Be Reduced?. European Heart Journal Supplements, 2023, 25, C20-C26.	2.9	4
408	Aspirin Deprescribing in Patients on Oral Anticoagulation for Atrial Fibrillation or Venous Thromboembolism: A National Survey of Clinician Practices. JACCP Journal of the American College of Clinical Pharmacy, 2023, 6, 690-700.	2.0	4
409	Trends in Off-Label Indications of Non-Vitamin K Antagonist Oral Anticoagulants in Acute Coronary Syndrome. Reviews in Cardiovascular Medicine, 2023, 24, 180.	2.5	2
410	Performance of DAPT Score and ESC Criteria for Predicting Clinical Outcomes in Chinese Patients With Acute Coronary Syndrome. International Journal of General Medicine, 2023, 16, 2867-2876.	2.5	0
411	Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients With Peripheral and Chronic Coronary Artery Disease: An Updated Review. Journal of Clinical Medicine, 2023, 12, 5284.	3.8	8
412	Comparison of Different Chronic Maintenance Antithrombotic Strategies in Patients With Coronary Artery Disease: A Systematic Review and Network Meta-Analysis. Cardiovascular Therapeutics, 2023, 2023, 5446271.	3.0	2
413	Phenotype-Directed Clinically Driven Low-Dose Direct Oral Anticoagulant for Atrial Fibrillation. Future Cardiology, 2023, 19, 405-417.	1.2	0
414	2023 ESC Guidelines for the Management of Acute Coronary Syndromes. European Heart Journal, 2023, 44, 3720-3826.	14.7	5,385

#	Article	IF	Citations
415	Long-Term Outcomes Among Stable Post-Acute Myocardial Infarction Patients Living in Rural Versus Urban Areas: Insights From the Prospective, Observational TIGRIS Registry. Open Heart, 2023, 10, e002326.	3.5	2
416	2023 ESC Guidelines for the Management of Acute Coronary Syndromes. European Heart Journal: Acute Cardiovascular Care, 2024, 13, 55-161.	4.0	429
417	Rivaroxaban, a Direct Inhibitor of Coagulation Factor Xa, Attenuates Adverse Cardiac Remodeling in Rats by Regulating the PAR-2 and TGF-β1 Signaling Pathways. PeerJ, 2023, 11, e16097.	2.9	8
418	Non-Vitamin K Antagonist Oral Anticoagulants in Differentiated Approach to the Use in Cardiological Practice: Literature Review. Ukrainian Journal of Cardiovascular Surgery, 2023, 31, 111-126.	0.2	0
419	Improving Risk Stratification in People With Previous Manifestations of Cardiovascular Disease: One Size Does Not Fit All in Secondary Prevention. European Journal of Preventive Cardiology, 2024, 31, 216-217.	6.1	1
420	Факторы, определяющие прогноз после плановой реваскуляризации миокарда у больных ишемической болезнью сердца с мультифокальным атеросклеротическим поражением. Cardiovascular Therapy and Prevention (Russian Federation), 2023, 22, 3689.	1.4	1
421	Comparison Efficacy and Safety of Different Antiplatelet or Anticoagulation Drugs in Chronic Coronary Syndromes Patients: A Bayesian Network Meta-Analysis. Medicine (United States), 2023, 102, e36429.	2.1	2
422	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care, 2024, 47, S179-S218.	20.9	547
423	Prognostic Value of CT-Derived Fractional Flow Reserve and Fat Attenuation Index in Patients With Suspected Coronary Artery Disease: A Sex-Disaggregated Analyses. BMC Cardiovascular Disorders, 2023, 23, 1-9.	3.3	15
424	Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long?. Medical Clinics of North America, 2024, 108, 539-551.	5.3	1
425	Pharmacotherapy and Revascularization Strategies of Peripheral Artery Disease. Current Problems in Cardiology, 2024, 49, 102430.	4.1	10
426	Arzneiverordnungs-Report 2023. , 2023, .		36
427	Correlation Between Blood Cadmium Levels and Platelet Characteristics, as Well as Their Impact on Susceptibility to Coronary Heart Disease: Findings From NHANES 2005–2018 Data. Cardiovascular Toxicology, 2024, 24, 335-344.	3.6	5
428	Chinese Expert Consensus on Anti-Thrombotic Therapy for Pan-Vascular Diseases (2023 Edition). Cardiology Plus, 2024, 9, 49.	1.7	10
429	Современные стратегии терапии СД 2 у пациентов со стабильной ишемической болезнью сердца. Старые цели, новые возможности (обзор литературы). Russian Journal of Cardiology, 2024, 29, 5689.	1.9	1
430	Efficacy and Safety of Combination Therapy With Low-Dose Rivaroxaban in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2024, 13, 2033.	3.8	1
431	Characteristics of the Russian Population of Patients With Coronary Artery Disease or Peripheral Artery Disease in the XATOA Registry. Rational Pharmacotherapy in Cardiology, 2024, 20, 241-248.	0.6	0
432	Antiplatelet Treatment With Dual Pathway Inhibition: A Pathway of Consistency?. European Cardiology Review, 2024, 19, e11.	2.4	0

#	Article	IF	Citations
433	Effect of Peripheral Interventions in Patients With Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses From the XATOA Registry. European Journal of Vascular and Endovascular Surgery, 2024, 0, 784-795.	3.2	3
434	Gene Therapy by Virus-Like Self-Spooling Toroidal DNA Condensates for Revascularization of Hindlimb Ischemia. Journal of Nanobiotechnology, 2024, 22, 1-16.	14.8	6
435	Antithrombotic Therapy in Acute Coronary Syndrome. Interventional Cardiology Clinics, 2024, 13, 507-516.	1.1	1
436	Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions. Journal of the American College of Cardiology, 2024, 84, 744-760.	12.0	49
437	Supporting Appropriate Use of Extended Dual Antiplatelet Therapy Post-Myocardial Infarction Based on an Innovative 12-Month Ticagrelor Virtual Service. Frontiers in Cardiovascular Medicine, 2024, 11, 1399899.	3.2	0
438	Effectiveness of Low-Dose Rivaroxaban in Preventing Recurrent Major Adverse Cardiovascular Events in Coronary Artery Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Coronary Artery Disease, 2024, 35, 614.	2.2	3
439	Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions. JACC: Cardiovascular Interventions, 2024, 17, 2325-2336.	5.0	16
440	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care, 2025, 48, S207-S238.	20.9	322
441	The Role of Coronary Computed Tomography Angiography in the Diagnosis, Risk Stratification, and Management of Patients With Diabetes and Chest Pain. Reviews in Cardiovascular Medicine, 2024, 25, 442.	2.5	5
442	Влияние антитромботической терапии на факторы риска развития сердечно-сосудистых осложнений у пациентов с ишемической болезнью сердца и сахарным диабетом. Акцент на гиперкоагуляцию. Kardiologiya, 2024, 64, 86-95.	0.9	0
443	Dual Pathway Inhibition in Patients With Peripheral Artery Disease in Germany. Vasa - European Journal of Vascular Medicine, 2025, 54, 142-149.	2.7	1
444	Ишемическая болезнь сердца в молодом возрасте: Современные тенденции и перспективы в диагностике и лечении. Klinicheskaia Meditsina, 2025, 102, 689-697.	0.3	0
445	Dual Pathway Inhibition in Patients With Coronary Artery Disease (CAD) in Clinical Practice in Germany: Results From the German CAD Subgroup of the XATOA Registry. Clinical Research in Cardiology, 2025, .	3.9	0
446	Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban With or Without Aspirin Compared to Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Iran. BMC Health Services Research, 2025, 25, 1-12.	3.8	2
447	TwPAD Registry: A Prospective, Multicenter Registry of Chronic Peripheral Arterial Disease Involving Lower Limbs in Taiwan. Journal of the Chinese Medical Association, 2025, 88, 389.	2.2	0
448	Chronic Coronary Syndrome and New-Onset Atrial Fibrillation or Venous Thromboembolism: How Best to Manage Antithrombotic Therapy Strategies. European Heart Journal - Cardiovascular Pharmacotherapy, 2025, 11, 451-458.	5.0	2
449	Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease. US Cardiology Review, 2025, 19, e11.	2.3	7
450	Arzneiverordnungs-Report 2024. , 2025, .		17

#	Article	IF	Citations
451	Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Клинические рекомендации 2024. Russian Journal of Cardiology, 2025, 30, 6306.	1.9	71
452	Extended Dual Antithrombotic Therapy in Patients With Chronic Coronary Syndrome - Which Agent Should Be Added to Aspirin?. Cardiology Journal, 2025, 32, 321-327.	1.7	1
453	Impact of Polyvascular Disease on Long-Term Prognosis of Patients With Acute Coronary Syndrome—A Retrospective Cohort Study in Italy. Journal of Clinical Medicine, 2025, 14, 4158.	3.8	0
454	Inflammation-Related 5-Hydroxymethylation Signatures as Markers for Clinical Presentations of Coronary Artery Disease. Cardiovascular Diabetology, 2025, 24, 1-19.	15.7	5
455	Outcomes of 10 mg Rivaroxaban in Nonvalvular Atrial Fibrillation Patients With CrCl ≥ 50 mL/Min: A Retrospective Cohort Study. Cardiovascular Therapeutics, 2025, 2025, 7021330.	3.0	1
456	Comparative Efficacy and Safety of Anticoagulant Therapies in Coronary Artery Disease: A Network Meta-Analysis of Randomized Controlled Trials. BMC Cardiovascular Disorders, 2025, 25, 1-12.	3.3	2
457	Coronary Artery Disease and Atherosclerosis in Other Vascular Districts: Epidemiology, Risk Factors and Atherosclerotic Plaque Features. Life, 2025, 15, 1226.	4.3	16
458	Эффективность и безопасность различных режимов многокомпонентной антитромботической терапии у больных с мультифокальным атеросклерозом (исследование реальной клинической практики). Cardiovascular Therapy and Prevention (Russian Federation), 2025, 24, 4346.	1.4	0
459	Antithrombotic Therapy After Coronary Artery Bypass Graft Surgery: A Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS). European Journal of Cardio-thoracic Surgery, 2025, .	2.2	5
460	Antithrombotic Therapy After Coronary Artery Bypass Graft Surgery: A Clinical Consensus Statement of the ESC Working Group on Cardiovascular Surgery, the ESC Working Group on Cardiovascular Pharmacotherapy, and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2026, 47, 2419-2436.	14.7	17
461	MACE and MALE Outcome With Rivaroxaban Following Endovascular Peripheral Arterial Intervention in Diabetes: A Real-World Study. International Journal of Diabetes in Developing Countries, 2026, 46, 1-6.	1.0	0
462	Protocolo de prevención primaria y secundaria de la cardiopatía isquémica. Medicine, 2025, 14, 2595-2601.	0.1	0
463	Cardiovascular Disease and Risk Management. , 2025, .		0
464	Diretriz de Síndrome Coronariana Crônica – 2025. Arquivos Brasileiros De Cardiologia, 2025, 122, e20250619.	1.2	7
465	Protocolo terapéutico de la antiagregación y la anticoagulación en la cardiopatía isquémica. Medicine, 2025, 14, 2631-2637.	0.1	0
466	Síndrome coronario agudo sin elevación del segmento ST. Medicine, 2025, 14, 2603-2613.	0.1	0
467	Varón de 58 años fumador, hipertenso y dislipidémico con dolor torácico agudo retroesternal, disnea y sudoración profusa. Medicine, 2025, 14, 2644.e1-2644.e3.	0.1	0
468	Rivaroxaban Does Not Alter Carotid Plaque Echolucency, Volume, or Neovascularisation. European Journal of Vascular and Endovascular Surgery, 2026, 71, 354-363.	3.2	2

#	Article	IF	Citations
469	Natural History and Outcomes of Medically Treated Coronary Artery Disease: Insights From Reconstructed Individual Patient Data of 29 Randomized Trials. Clinical Research in Cardiology, 2025, .	3.9	6
470	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care, 2026, 49, S216-S245.	20.9	152
471	Dual Pathway Inhibition: Redefining the Secondary Prevention COMPASS in Chronic Coronary Artery Disease. International Journal of Angiology, 2025, .	1.1	0
472	Vascular Aging as a Driver of Thrombosis in Older Adults: From Mechanisms to Gerotherapeutics. , 2025, 2, 202513.		0
473	Long-Term Outcomes of Simultaneous Carotid Endarterectomy and Coronary Artery Bypass Grafting Depending on Lower Extremity Atherosclerosis. Kardiologicheskii Vestnik, 2025, 20, 164-172.	0.4	0
474	Multifocal Atherosclerosis: The Possibilities of Antithrombotic Therapy. Scientific Bulletin of the Omsk State Medical University, 2024, 4, 2-12.	0.2	0
475	Contemporary and Global Perspectives in Physical Therapy. , 2026, .		8
476	Arzneiverordnungs-Report 2025. , 2026, .		5
477	Facteurs biologiques et morphologiques prédictifs de récurrences ischémiques et hémorragiques dans l'athéro-thrombose. , 0, .		0
478	Antithrombotic Therapy in Coronary Artery Disease: Strategy Choice Based on Comorbidity. A Review. Consilium Medicum, 2026, 28, 28-35.	0.4	0
479	CSC Guidelines for Percutaneous Coronary Intervention (2025). Cardiology Discovery, 2026, 6, 69-93.	0.6	0
480	Age-Related Efficacy of Aspirin in Secondary Prevention of Coronary Artery Disease: START-ANTIPLATELET Registry and Meta-Analysis of Randomized Trials. American Journal of Medicine, 2026, .	3.2	0
481	Antiplatelet Therapy for Patients With Stable Coronary Artery Disease Receiving Oral Anticoagulation: A Meta-Analysis of Randomized Controlled Trials. Journal of Cardiology, 2026, 88, 136-141.	3.8	0
482	Characteristics, Readmission Patterns and Trends in Hospitalisations for Chronic Coronary Disease in Western Australia, 2005 to 2022. International Journal of Cardiology, 2026, 460, 134589.	3.2	1
483	Approaches to Plaque Imaging by CCTA. , 2025, .		0
484	Effect of Low-Dose Rivaroxaban Plus Aspirin on 18F-FDG PET/CT-Detectable Carotid Plaque Inflammation: A Randomized Trial. European Heart Journal Cardiovascular Imaging, 2026, 27, 1728-1740.	4.7	0
485	Rivaroxaban. , 2026, .		0
486	Role of Inflammation in the Development of Heart Failure After Myocardial Infarction. Reviews in Cardiovascular Medicine, 2026, .	2.5	0

#	Article	IF	Citations
487	Method of Treating Patients With a Factor Xa Inhibitor, Aspirin, and Verapamil. , 2020, .		0
488	Method of Treating Patients With a Factor Xa Inhibitor, Aspirin, and Verapamil. , 2020, .		0
489	Reducing the Risk of Cardiovascular Events. , 2020, .		0